Schrodinger reported strong Q4 2023 results, but weak guidance for 2024, causing a significant drop in the share price. The demand environment continues to impact the software business, with growth ...

Schrodinger reported robust software and drug discovery revenue in the second quarter. Lilly's planned multi-billion-dollar acquisition of Morphic also provides another validation point for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Schrödinger’s updated fair value estimate has shifted from US$20.88 to US$22.29 per share, putting fresh attention on how the ...

If AI evolves, we might be able to reach drugs that were previously impossible to create. This is one of the reasons for the ...

Disgruntled shareholders began ditching the stock en masse after the company announced lackluster guidance. Schrodinger expects to generate between $124 million and $142 million in revenue this year ...

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced a research collaboration and license agreement with Novartis to advance multiple development candidates into Novartis’s ...

NEW YORK--(BUSINESS WIRE)--Aug. 5, 2026-- Schrödinger, Inc. (Nasdaq: SDGR) today announced a strategic agreement with Bristol Myers Squibb (BMS) to deploy Bunsen, Schrödinger's agentic AI co-scientist ...

Goldman Sachs raised the firm’s price target on Schrodinger (SDGR) to $28 from $27 and keeps a Neutral rating on the shares. The company’s Q3 results and announced deal with Novartis (NVS) involving ...

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today provided an update on its progress across the business in 2024 and announced its strategic priorities for 2025. “We are very proud of ...